Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Additional Locations, Minnesota Clinical Trials

A listing of Additional Locations, Minnesota clinical trials actively recruiting patient volunteers.

RESULTS

Found (202) clinical trials

Phase 2 Study of Glesatinib Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer

Glesatinib is an orally administered multi-targeted tyrosine kinase inhibitor (TKI) that primarily targets the Axl and Mesenchymal-Epithelial Transition (MET) receptors. Sitravatinib is an orally-available, potent small molecule inhibitor of a closely related spectrum of receptor tyrosine kinases (RTKs) including MET, Axl, MERTK, VEGFR family, PDGFR family, KIT, FLT3, Trk family, ...

Phase

1.24 miles

Learn More »

A Phase IIA Study of Blood Pressure Comparing Daprodustat to an Erythropoiesis-stimulating Agent in Subjects With Anemia of Chronic Kidney Disease on Hemodialysis

This will be an open-label, randomized, parallel-group study in hemodialysis-dependent (HD) subjects with anemia associated with chronic kidney disease (CKD), designed to compare the effects of daprodustat to epoetin alfa on blood pressure (BP). After a 4-week screening and a 4-week erythropoesis-stimulating agent (ESA) washout period, on Day 1 subjects ...

Phase

1.24 miles

Learn More »

An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread

The purpose of this study is to determine whether nivolumab is an effective treatment for cancer that has advanced or has spread. Various tumor types may be eligible for enrollment.

Phase

1.24 miles

Learn More »

A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer

The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as LY3023414 in combination with enzalutamide in men with prostate cancer.

Phase

1.24 miles

Learn More »

Study of the Safety Tolerability and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function

This is a randomized, double-blind, parallel group, placebo-controlled study, in two sequential parts to evaluate the renal safety, tolerability and pharmacokinetics of LHW090 in patients with moderately impaired renal function.

Phase

1.24 miles

Learn More »

A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

This is a nonrandomized study of ruxolitinib in combination with a standard multi-agent chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (ruxolitinib) in combination with the chemotherapy regimen. Part 2 will evaluate the efficacy of combination ...

Phase

1.24 miles

Learn More »

BGJ398 for Patients With Tumors With FGFR Genetic Alterations

The purpose of this signal seeking study is to determine whether treatment with BGJ398 demonstrates sufficient efficacy in select FGFR pathway-regulated solid tumors and/or hematologic malignancies to warrant further study.

Phase

1.24 miles

Learn More »

An Efficacy and Safety Study of JNJ-42756493 in Participants With Urothelial Cancer

This is a multicenter, open-label study (participants will know the identity of study drugs administered) to evaluate the efficacy and safety of JNJ-42756493 in participants with urothelial cancer. The study comprises a 30-days Screening Phase, a Treatment Phase comprised of 28-day treatment cycles that will continue until disease progression or ...

Phase

1.24 miles

Learn More »

Selumetinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors Non-Hodgkin Lymphoma or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

PRIMARY OBJECTIVES: I. To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with selumetinib (AZD6244 hydrogen sulfate) with advanced solid tumors (including central nervous system [CNS] tumors), non-Hodgkin lymphomas or histiocytic disorders that harbor activating genetic alterations in the MAPK pathway. SECONDARY OBJECTIVES: ...

Phase

1.24 miles

Learn More »

A Study to Evaluate the Safety Tolerability and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer or Metastatic Colorectal Cancer

The drug being tested in this study is called TAK-931. TAK-931 blocks the function of a specific protein in the body called CDC7 kinase. TAK-931 is being tested in participants with metastatic pancreatic cancer or metastatic colorectal cancer plus a cohort of US patients with metastatic cancer with no other ...

Phase

1.24 miles

Learn More »